【ScinoPharm】Announcement of the Board of Directors' approval of the Q1 2026 Consolidated Financial Report
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
ScinoPharm announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026, reporting operating revenue of NT$659,708 thousand, operating profit of NT$8,488 thousand, and basic earnings per share of NT$0.02.